Loading clinical trials...
Loading clinical trials...
An Open-Label, Multicenter Study to Evaluate Continued Safety of FB-401 for up to 48 Weeks in Children, Adolescent and Adult Subjects (Ages 2 Years and Older) With Mild to Moderate Atopic Dermatitis Previously Enrolled in FB401-01 Phase 2 Study
Conditions
Interventions
FB-401
Locations
8
United States
Center for Dermatology Clinical Research, Inc.
Fremont, California, United States
Multi-Specialty Research Associates, Inc.
Lake City, Florida, United States
MedaPhase, Inc
Newnan, Georgia, United States
DS Research
Clarksville, Indiana, United States
DS Research
Louisville, Kentucky, United States
Cyn3rgy Research
New Brighton, Minnesota, United States
Start Date
June 2, 2021
Primary Completion Date
September 30, 2021
Completion Date
September 30, 2021
Last Updated
October 28, 2021
NCT07262983
NCT06389136
NCT06342713
NCT07223697
NCT07290803
NCT07265479
Lead Sponsor
Forte Biosciences, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions